In vitro activity, safety and in vivo efficacy of the novel bumped kinase inhibitor BKI-1748 in non-pregnant and pregnant mice experimentally infected with Neospora caninum tachyzoites and Toxoplasma gondii oocysts

In vitro activity, safety and in vivo efficacy of the novel bumped kinase inhibitor BKI-1748 in non-pregnant and pregnant mice experimentally infected with Neospora caninum tachyzoites and Toxoplasma gondii oocysts

Bumped kinase inhibitors (BKIs) target the apicomplexan calcium-dependent protein kinase 1 (CDPK1). BKI-1748, a 5-aminopyrazole-4-carboxamide compound when added to fibroblast cells concomitantly to the time of infection, inhibited proliferation of apicomplexan parasites at EC50s of 165 nM (Neospora...

Full description

Bibliographic Details
Main Authors: Dennis Imhof, Nicoleta Anghel, Pablo Winzer, Vreni Balmer, Jessica Ramseier, Kai Hänggeli, Ryan Choi, Matthew A. Hulverson, Grant R. Whitman, Samuel L.M. Arnold, Kayode K. Ojo, Wesley C. Van Voorhis, J. Stone Doggett, Luis M. Ortega-Mora, Andrew Hemphill
Format: Article
Language:English
Published: Elsevier 2021-08-01
Series:International Journal for Parasitology: Drugs and Drug Resistance
Subjects:
Bumped kinase inhibitors
Calcium dependent protein kinase inhibitor
Neosporosis
Toxoplasmosis
Pregnancy
Tachyzoites
Online Access:http://www.sciencedirect.com/science/article/pii/S2211320721000208

Internet

http://www.sciencedirect.com/science/article/pii/S2211320721000208

Similar Items